| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 695 | 687 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -7,925 | -28,729 |
| Cash and cash equivalents at beginning of period | 105,161 | - |
| Cash and cash equivalents at end of period | 97,236 | - |
Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc. (TRDA)